Oxidative stress is involved in the tolerance to ischemia/reperfusion (I/R) injury. Because angiotensin II type-1 receptor blockers (ARBs) inhibit oxidative stress, it is concerned that ARBs abolish the tolerance to I/R injury.
Introduction
Oxidative stress has been implicated in the pathogenesis of cardiac hypertrophy, congestive heart failure and ischemia/reperfusion (IR) injury. Oxidative stress was initially thought to be a detrimental event precipitating in cellular dysfunction by attacking a variety of biomolecules (18) . Recently, a new paradigm of redox signaling has emerged whereby reactive oxygen species (ROS) and oxidants can function as intracellular signaling molecules that convert death signal into a survival signal (7). This concept is exemplified by ischemic preconditioning (IPC) where mild and transient oxidative stress confers tolerance to subsequent lethal cellular stress (23). The redox-sensitive nature of IPC has been substantiated by the use of antioxidants, such as N-acetylcysteine and 2-mercaptopropionylglycine (MPG) which blocked IPC-induced cardioprotection by eliminating oxidative stress (2, 6).
In addition, it has been revealed that ROS and nitric oxide (NO) generated during the preconditioning stimuli triggers late cardioprotection by upregulating inducible nitric oxide synthase (iNOS) (4, 5) . Upregulation of iNOS is also observed in the hypertensive heart (13) and the cardiomyopathic heart in which the redox-sensitive upregulation of iNOS plays an obligatory role in the tolerance to I/R injury (16) 
Therefore, it is possible that the use of antioxidants compromises tolerance to I/R injury in diseased hearts by abrogating the redox-sensitive upregulation of iNOS.
The renin-angiotensin system is locally activated in the heart under various disease conditions (10, 27) . Angiotensin II acting through high affinity cell surface angiotensin II type-1 (AT1) receptors modulates H91533-2007 R2 5 5 cardiovascular homeostasis by exerting vasoconstriction and promoting myocardial hypertrophy and fibrosis, thereby contributing pathological remodeling during the development of heart failure (19). Accumulating evidence suggests that such detrimental effects of AT1 receptor activation are mediated at least in part by oxidative stress through the activation of NADPH oxidase system (7). It has been demonstrated that AT1 receptor blockers (ARBs) inhibit oxidative stress in the hypertensive heart (3, 9).
This raises a concern that the use of ARBs may eliminate the tolerance to I/R injury in the hypertensive heart which is chronically exposed to oxidative stress by activation of AT1 receptors. On the contrary, accumulating evidence has indicated that pre-ischemic treatment with ARBs confers cardioprotection against I/R injury in the normotensive hearts as demonstrated by improved post-ischemic cardiac function and reduced infarct size (11, 14, 24) . Nevertheless, the effect of ARBs on I/R injury in the hypertensive heart has not been investigated. Therefore, the present study was undertaken to address the question as to whether inhibition of oxidative stress by a genuine antioxidant and an ARB modulates the tolerance to I/R injury in the hypertensive heart. The Dahl salt-sensitive (DS) hypertension rat is a useful model for investigating the effect of local activation of the renin-angiotensin system in the heart. The circulatory renin-angiotensin system is suppressed during the development of hypertension in these rats on high-salt intake (26, 33) H91533-2007 R2 6 6 and this model of "low-renin hypertension" is in general considered to be unresponsive to treatment with blockers of the renin-angiotensin system (12). Accordingly, treatment with ARBs prevents the effect of locally elevated angiotensin II without affecting blood pressure. Using this rat model we were able to show that a genuine antioxidant and an ARB inhibit oxidative stress and upregulation of iNOS but only an AT1 blocker preserves the tolerance to I/R injury in the DS rat heart.
Materials and Methods

Animals
All experiments were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals (NIH publication No. 85-23, revised 1996) and approved by the Kansai Medical University Institutional Animal Care and Use Committee.
Male inbred DS rats and Dahl salt-resistant (DR) rats were purchased from (Japan SLC Inc. (Shizuoka, Japan). After they were weaned, the rats were fed a diet containing 0.3% NaCl until the age of 6 weeks. Thereafter, the rats were fed a diet containing 8% NaCl. The rats were weighed, and their systolic blood pressure was measured by the tail-cuff system (BP-98A, Softron, Tokyo, Japan) just before echocardiography and surgical preparation. Transthoracic echocardiography was performed using a SONOS-7500 (Philips Medical Systems, Andover, MA) equipped with a 6-15 MHz transducer (Model 21390A, Philips) as described previously (16) .
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Briefly, from the cardiac short axis (papillary muscle level), an M-mode trace of the LV was obtained and septal diastolic wall thickness as well as the LV end-diastolic dimension (LVEDD) and the LV end-systolic dimension (LDESD) were measured at the widest and the narrowest dimensions, respectively. LV fractional shortening (LVFS) was calculated as: %FS = (LVEDD-LVESD)/LVEDD×100.
Surgical preparation
Pentobarbital-anesthetized (60 mg/kg, i.p.) rats were intubated for positive pressure ventilation with oxygen-enriched room air. A catheter was positioned in the abdominal cavity to allow intraperitoneal administration of pentobarbital for maintenance of anesthesia. Rectal temperature was continuously measured and maintained at 36.5-37.5°C. Millar-tip catheter (2F) (Millar Instrument, Co., Houston, TX) was inserted into the left ventricle (LV) via the left carotid artery to monitor LV pressure.
A left thoractomy was performed at the fifth intercostal space and the pericardium was opened to expose the heart. The left coronary artery was ligated 1-2 mm from its origin by a 7-0 silk suture with an atraumatic needle and ends of this ligature were passed through a small vinyl tube to form a snare. After the completion of the surgical procedure, the heart was returned to its normal position in the thorax. The thoracic cavity was covered with saline-soaked gauze to prevent the heart from drying. The animals were then allowed to stabilize for 15 min before LAD ligation. 
Experimental protocol
The DR and the DS rats fed the high-salt diet for 5 weeks were randomly divided into 14 groups (Figure 1 ). The control groups of rats were fed with the high-salt diet for additional 7 days without any drug treatment and subjected to coronary artery occlusion and reperfusion. Second groups of rats were treated with an antioxidant 2-mercaptopropionylglycine (MPG, 100 mg/kg/day, i.p) for 7 days before coronary artery occlusion and reperfusion. Third groups of rats were administered an ARB, losartan (30 mg/kg/day) in the drinking water for 7 days before coronary artery occlusion and reperfusion. Fourth groups of rats were treated with an iNOS selective inhibitor 1400W (10 mg/kg, i.p) or a non-selective NOS inhibitor, Nω-nitro-L-arginine methyl ester (L-NAME; 100 mg/kg, i.p) 30 minutes before coronary artery occlusion and reperfusion. Fifth groups of rats were administered losartan for 7 days and treated with 1400W or L-NAME 30 minutes before coronary artery occlusion and reperfusion.
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Measurements of infarct size
The rats were euthanized with sodium pentobarbital (100 mg/kg, i.p.) after 2 hours of reperfusion, and the left coronary artery was religated in the same location as before.
Evans blue dye (1.2 ml of a 2% solution) was injected into the carotid artery catheter inserted into the heart to delineate the ischemic zone from the nonischemic zone. The heart was rapidly excised and serially sectioned along the long axis in 1-mm-thick sections, which were then incubated in 1.0% 2,3,5-triphenyltetrazolium chloride for 5 min at 37°C to demarcate the viable and nonviable myocardium within the risk zone.
Each of the five 1-mm-thick myocardial slices was weighed and digitally photographed for determining infarct size as a percentage of risk region and the areas of infarction, risk, and nonischemic LV were assessed by a blinded observer using computer-assisted planimetry (Win Roof, Mitani Co., Fukui, Japan). All of the procedures for area at risk and infarct size determination have been previously described (15) .
Determination of MDA+HNE in tissue preparation
The rats were euthanized as described before 6 weeks after the high salt diet, and the heart was rapidly excised and stored in liquid nitrogen until the assay. On the day of analysis, tissue samples were washed in ice-cold NaCl 0.9%, blotted on H91533-2007 R2 10 absorbent paper and weighed. Each sample was then ground in a small volume of ice-cold 20 mM Tris-HCl buffer pH 7.4, in a 1:10 w/v ratio, and homogenized using a Teflon pestle. After centrifugation at 3,000g for 10 minutes at 4°C, the supernatant was used for the determination of malondialdehyde (MDA) plus 4-hydroxy-noneal (HNE), using an assay kit (BIOXYTECH LPO-586, Oxis
Research, Foster, CA). The protein concentration was determined with a Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA).
Western blot analysis
Heart samples stored in liquid nitrogen were ground with lysis buffer containing 30mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride, and a protease inhibitor cocktail Complete (Roche Diagnostics, Mannheim, Germany). The protein concentration was determined as described before. The lysate samples were separated by a 7.5% SDS-PAGE and the separated proteins were transferred to a polyvinylidene-difluoride membrane with a transfer buffer containing 25 mM Tris, 192 mM glycine and 10% methanol. The membranes were blocked with 5% skimmed milk and incubated in primary antibodies specific for iNOS (Santa Cruz Biotechnology, Santa Cruz, CA), eNOS (Cell Signaling Technology, Beverly, MA) and phospho-eNOS (Ser-1177) (Cell Signaling Technology) and subsequently incubated with a peroxidase-conjugated secondary antibodies and developed using an enhanced chemiluminescence detection system (Amersham Biosciences, Tokyo, Japan) according to the manufacturer's H91533-2007 R2 11 11 instructions. The immunolabeling was quantified with a densitometric analysis using an image analyzing soft ware Win Roof (Mitani Co.). Consistency in the data analysis was ensured by normalization of each immunoblot signal to the corresponding Coomassie Blue stain signal as described previously (22).
Statistical analysis
All numerical data are expressed as mean ± SE. Statistical analysis of data within and between groups was performed with one-way ANOVA followed by the Bonferroni post hoc test or two-way repeated measures ANOVA when comparisons were made at different time points.
Results
Baseline characteristics of DS and DR rat heart
Baseline hemodynamic characteristics of the DS and the DR rats fed with high-salt diet for 6 weeks in the presence or absence of MPG or losartan for the last 7 days are shown in Table 1 . Systolic blood pressure (SBP) was significantly higher in the DS rats compared to the DR rats. Treatment with MPG and losartan had no significant effect on SBP and heart rate in the DS and the DR rats. Echocardiography showed that septal wall thickness was significantly greater in the DS rats compared to the DR rats.
Although there was no significant difference in end-diastolic diameter (EDD) between the DR and the DS rats, end-systolic diameter (ESD) was significantly smaller in the H91533-2007 R2 12 12 DS rats compared to the DR rats. Consequently, fractional shortening (FS) was significantly greater in the DS rats. Treatment with MPG and losartan did not affect septal wall thickness, EDD and ESD in the DS and the DR rats.
Effect of MPG and losartan on the generation of MDA and HNE
The amount of MDA+HNE was significantly increased in the DS rat heart compared to the DR rat heart (Figure 2 ). MPG and losartan inhibited the increase in MDA+HNE in the DS rat heart.
Effect of MPG and losartan on the expression of iNOS
The expression of iNOS was significantly increased in the DS rat heart compared to the DR rat heart (Figure 3 ). MPG and losartan inhibited the increase in iNOS expression in DS rat hearts.
Effect of MPG and losartan on the expression of total eNOS and phospho-eNOS
Phosphorylation of eNOS on Ser-1177 was thought to be an indicator of activation of eNOS (8). MPG and losartan had no significant effect on the expression of total eNOS and phospho-eNOS and the ratio of H91533-2007 R2 13 13 phospho-eNOS/total eNOS in the DR rat heart (Figure 4 ). There was no difference in total eNOS expression between the DR and DS rat hearts.
However, losartan but not MPG increased the expression of phospho-eNOS and the ratio of phospho-eNOS/total eNOS in the DS rat heart.
Effect of MPG and losartan on the LV function
LV systolic pressure (LVSP) was significantly higher in the DS rats before coronary artery occlusion compared to the DR rats (Table 2) .
Neither MPG nor losartan affected LVSP and LV end-diastolic pressure (LVEDP) in the DS and the DR rats. LVSP remained significantly higher in the DS rats during coronary artery occlusion and reperfusion. However, LVSP significantly decreased and LVEDP significantly increased during reperfusion in the DS rats treated with MPG, although the same treatment had no effect on LVSP and LVEDP during reperfusion in the DR rats. In contrast, losartan did not affect LVSP and LVEDP during reperfusion in the DS rats.
Effect of MPG and losartan on infarct size
Infarct size 2 hours after reperfusion was comparable between the DS H91533-2007 R2 14 14 and the DR rat hearts ( Figure 5 ). MPG had no effect on infarct size in the DR rat hearts but significantly increased infarct size in the DS rat hearts.
In contrast, losartan did not affect infarct size in the DS rat hearts.
Effect of 1400W and L-NAME on the losartan-induced cardioprotection
We then investigated whether NOS plays any roles in I/R injury or protection in the DS rat heart. Brief treatment with 1400W or L-NAME before coronary artery occlusion had no effect on the LV function during reperfusion and infarct size in the DR rats (Table 3 and Figure 6 ).
However, 1400W and L-NAME significantly decreased LVSP and increased LVEDP during reperfusion and significantly increased infarct size in the DS rats. In contrast, 1400W had no effect on the LV function during reperfusion and infarct size in the DS rats treated with losartan (Table 4 and Figure 7) . However, brief treatment with L-NAME before coronary artery occlusion significantly decreased LVSP and increased LVEDP during reperfusion and significantly increased infarct size in the DS rats treated with losartan.
Discussion
Although oxidative stress has been implicated in the pathophysiology H91533-2007 R2 15 of I/R injury, it also promotes redox-sensitive signal transduction that protects cell from lethal I/R injury (7, 21). Because oxidative stress is increased in the hypertensive heart (25), we attempted to address the question as to whether any protective mechanisms against I/R injury are installed in the hypertensive heart through oxidative stress and whether inhibition of oxidative stress by a genuine antioxidant and an antihypertensive drug ARB modulates the tolerance to I/R injury in the hypertensive heart. The present study demonstrated that the DS rats with a high-salt diet for 6 weeks were exposed to oxidative stress as shown by an increase in MDA+4-HNE in the heart. Moreover, oxidative stress promoted iNOS expression in the DS rat heart, because MPG abrogated the increase in MDA+4-HNE and the expression of iNOS. Such redox-sensitive upregulation of iNOS appears to be crucial in acquisition of the tolerance to I/R injury in the DS rat heart because MPG and 1400W deteriorated the LV function during reperfusion and increased infarct size in this heart. In contrast to MPG, inhibition of oxidative stress and upregulation of iNOS by losartan did not affect the LV function and infarct size after I/R in the DS rat heart. These results suggest that losartan preserved the tolerance to I/R injury through the mechanism independent of oxidative stress and iNOS in the DS rat heart. On the other hand, losartan increased phosphorylation of eNOS in the DS heart, suggesting that eNOS was activated by losartan in the DS rat heart. Although preischemic treatment H91533-2007 R2 16 with 1400W had no effect on the LV function and infarct size after coronary artery occlusion and reperfusion in the DS rat treated with losartan, L-NAME deteriorated the LV function and increased infarct size in these rat hearts, indicating that eNOS activation is involved in the cardioprotection mediated by losartan. However, because L-NAME is a non-selective NOS inhibitor, the role of nNOS can not be eliminated at present.
The mechanism of cardioprotection against I/R injury afforded by ARBs has not been completely understood. Blocking AT1 receptors renders local angiotensin II more accessible to angiotensin II type 2 (AT2) receptors.
Resultant activation of AT2 receptors increases generation of bradykinin which has been implicated as a potential mechanism for ARB-mediated cardioprotection (14, 17) . Activation of eNOS is a downstream effect of increased bradykinin generation (1, 28) . eNOS activation has been shown to be indispensable for cardioprotection against I/R injury mediated by late IPC (30), dipyridamole-atorvastatin combination (31), and a volatile anesthetic agent isoflurane (29). The results of the present study are consistent with a potential role of eNOS in preservation of the tolerance to I/R injury in the DS rat heart. The reason why losartan significantly increased eNOS phosphorylation and conferred cardioprotection only in the DS rat heart and not in the DR rat heart is probably because of less angiotensin II generation and less activation of AT2 receptors in the DR rat heart. Although we did not H91533-2007 R2 17 investigate the cardioprotective signals other than eNOS, Akt and protein kinase C-ε may constitute a cardioprotective signaling module with eNOS (32) .
The DS rats were the choice of the experimental model because hypertension in these rats is known to be not affected by AT1 blockers. This lack of anti-hypertensive effect is important to compare the effect of elimination of oxidative stress on cardioprotection of the AT1 blocker because lowering blood pressure by itself is protective against I/R injury. Although infarct size after I/R was comparable between the DR and the DS rat hearts, it is considered that the DS rat heart may be a more cardioprotective phenotype, and infarct size would be smaller in the DS rat heart if blood pressure is comparable between these rats. This assumption was confirmed by the observation that when the DS rats were fed with a low-salt diet for 4 days before experiments, blood pressure at the time of coronary artery occlusion was significantly decreased in these rats associated with significant reduction of infarct size compared to the DS rats fed continuously with a high-salt diet (Matsuhisa S and Otani H, unpublished observation). Moreover, iNOS expression remained increased after 4 days of a low-salt diet, and 1400W or L-NAME increased infarct size in the DS rat heart, indicating that iNOS-dependent tolerance to I/R injury was preserved for at least 4 days after a low-salt diet and a decrease of blood pressure.
The DS rats fed with a high-salt diet for 6 weeks developed LV hypertrophy associated with hypertension. Although LVEDD was not H91533-2007 R2 18 different between the DR and the DS rats, LVESD was significantly smaller in the DS rats. Consequently LVFS was significantly higher in the DR rats, indicating that the DS rat heart remained hyperdynamic after 6 weeks of high-salt diet. Although the DS rat heart had acquired the tolerance to I/R injury at this compensated stage of hypertension, it is unknown whether these hearts remained a cardioprotective phenotype at the de-compensated stage of hypertension when the DS rats are deteriorated to heart failure.
There is no definite answer to this question, however, it is possible that these hearts may not be tolerant to I/R injury after deterioration to heart failure. In line with this idea, Miki and associates (20) investigated whether or not post-infarction ventricular remodeling interferes with the preconditioning mechanism, a representative feature of ischemic tolerance. The investigators created myocardial infarction to induce remodeling by permanently ligating the left coronary artery in rabbits two weeks before isolation of the hearts. When the isolated buffer-perfused hearts were subjected to I/R injury, IPC with 2 episodes of 5-minute ischemia protected sham-operated but not remodeled hearts, indicating that the failing heart was not adequately preconditioned. Further studies are necessary to investigate whether or not ischemic tolerance and the preconditioning phenomenon are similarly lost after heart failure in the DS rat heart.
In conclusions, the DS rat heart at a compensated stage of hypertension is promoted to a cardioprotective phenotype through oxidative stress and upregulation of iNOS. Losartan preserves the tolerance to I/R injury by activating eNOS despite groups. The control groups of rats were fed with the high-salt diet for additional 7 days without any drug treatment and subjected to coronary artery occlusion (CAO) and reperfusion. Second groups of rats were treated with an antioxidant 2-mercaptopropionylglycine (MPG, 100 mg/kg/day, i.p) for 7 days before CAO and reperfusion. Third groups of rats were administered an ARB, losartan (30 mg/kg/day) in the drinking water for 7 days before CAO and reperfusion. Fourth groups of rats were treated with an iNOS selective inhibitor 1400W (10 mg/kg, i.p) or a non-selective NOS inhibitor, Nω-nitro-L-arginine methyl ester (NAME; 100 mg/kg, i.p) 30 minutes before CAO and reperfusion. Fifth groups of rats were administered losartan for 7 days and treated with 1400W or NAME 30 minutes before CAO and reperfusion. 
Figure 4
The ratio of eNOS/phospho-eNOS (p-eNOS). The Dahl salt-resistant (DR) and the Dahl salt-sensitive (DS) rats were treated with or without an 2-mercaptopropionylglycine (MPG) or losartan (Los) as described in Figure   1 . Western-blot analysis for eNOS and p-eNOS was performed as described in the Materials and the Methods. Each bar graph indicates mean±SEM of 5 experiments.
*p<0.05 compared to DR-control; #p<0.05 compared to DS-control.
Figure 5
The Dahl salt-resistant (DR) and the Dahl salt-sensitive (DS) rats were treated with or without 2-mercaptopropionylglycine (MPG) or losartan (Los) as described in Figure 1 . Infarct size after 30 minutes of left coronary artery occlusion and 2 hours of reperfusion is expressed as % area at risk. Each bar graph indicates mean±SEM of 5 experiments. *p<0.05 compared to DR-control; #p<0.05 compared to DS-control.
Figure 6
The Dahl salt-resistant (DR) and the Dahl salt-sensitive (DS) rats were treated with or without 1400W or Nω-nitro-L-arginine methyl ester (NAME) as described in Figure 1 . Infarct size after 30 minutes of left coronary artery occlusion and 2 hours of reperfusion is expressed as % area at risk. Each bar graph indicates mean ±SEM of 5 experiments. *p<0.05 compared to DR-control; #p<0.05 compared to DS-control.
Figure 7
The Dahl salt-resistant (DR) and the Dahl salt-sensitive (DS) rats were treated with 422±12  425±11  411±10  401±5  390±8  DR 1400W  403±11  401±10  398±8  389±6  381±6  DR NAME  410±13  408±14  406±12  395±12  383±12  DS control  413±11  411±11  399±9  393±7  386±8  DS 1400W  403±15  402±16  399±14  379±13  365±13  DS NAME  412±10  411±9  406±7  392±6  374±6 LVSP ( 8±1  8±1  15±1  14±1  12±1  DR 1400W  9±1  8±1  14±0  13±0  13±1  DR NAME  8±1  8±1  14±1  14±1  11±1  DS control  10±1  10±1  15±1  14±1  13±0  DS 1400W  8±1  8±0  17±1  16±0*#  14±1  DS NAME  9±1  9±1  16±1  17±1*#  14±2 DR, Dhal salt resistant; DS, Dahl salt sensitive; NAME, Nω-nitro-L-arginine methyl ester.
HR, heart rate; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end-diastolic pressure.
Data are expressed as mean±SEM of 5 experiments. *p<0.05 compared to DR control, #p<0.05 compared to DS control. 
